Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib[Annals of Hematology, (2015), DOI:10.1007/s00277-014-2272-0]

2015-06-01

Annals of Hematology , Volume 94 - Issue 6 p. 1079

Additional Metadata
Persistent URL	doi.org/10.1007/s00277-015-2356-5, hdl.handle.net/1765/83970
Journal	Annals of Hematology
Organisation	Department of Hematology
Citation APA Style AAA Style APA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Ammatuna, E., Eefting, M., van Lom, K., Kavelaars, F., Valk, P., & Touw, I. (2015). Erratum to: Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib[Annals of Hematology, (2015), DOI:10.1007/s00277-014-2272-0]. Annals of Hematology, 94(6). doi:10.1007/s00277-015-2356-5

See Also
article Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib E. Ammatuna (E.), M. Eefting (Matthias), K. van Lom (Kirsten), F.G. Kavelaars (François), P.J.M. Valk (Peter) and I.P. Touw (Ivo)

Publication